GlassScriptPhysician profile
Marc J Levine
NPI 1356306153
$15,315.07
in general payments reported to CMS, 2019-2025
28 companies · $22.52 in 2025
The $22.52 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,270 · 2020: $1,376 · 2021: $3,119 · 2022: $1,582 · 2023: $2,317 · 2024: $628 · 2025: $22.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742 · Travel and Lodging: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.79 |
| Travel and Lodging | $1,225.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $5,116.84 | 2019-2020 | |
| Boston Scientific Corporation | $2,322.45 | 2019-2023 | Avvigo Guidance System |
| Abbott Laboratories | $2,134.06 | 2021-2024 | Optis, Ultreon, Mini Trek |
| Shockwave Medical, INC | $1,171.07 | 2019-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $981.29 | 2019-2022 | |
| Abiomed | $565.49 | 2021-2024 | Impella |
| Philips North America LLC | $426.53 | 2019-2021 | |
| Medtronic, INC. | $406.18 | 2021-2023 | Micra, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $383.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $245.24 | 2019-2022 | |
| Penumbra, INC. | $243.07 | 2021-2022 | |
| Silk Road Medical, INC. | $223.09 | 2021-2022 | |
| Amgen INC. | $215.00 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $198.06 | 2019-2021 | |
| Pfizer INC. | $130.36 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $86.21 | 2019-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.42 | 2021 | |
| Biotronik INC. | $68.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $61.48 | 2019-2020 | |
| Cardiovascular Systems INC. | $50.20 | 2019-2020 | |
| Cardiva Medical, INC. | $40.46 | 2024-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Teleflex LLC | $38.10 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $35.72 | 2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $30.46 | 2021-2022 | |
| Esperion Therapeutics, INC. | $21.11 | 2021 | |
| Chiesi USA, INC. | $18.00 | 2023 | Kengreal, Cleviprex |
| Alnylam Pharmaceuticals INC. | $15.93 | 2019 | |
| Acacia Pharma INC | $15.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.